- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
AdvaMed's Ubl for PhRMA President?
September 24, 2015.
There is growing speculation online that Stephen J. Ubl, president and CEO of the Advanced Medical Technology Association (AdvaMed), will take over from John J. Castellani as the new president and CEO of PhRMA. PhRMA is expected to make an announcement confirming the appointment as early as next week.
Ubl has been president of AdvaMed since 2005. MDDI writes that in "just a few short years", he has "dramatically raised the profile of the medical device industry on Capitol Hill". The Hill.com named him one of the top Washington lobbyists back in 2007. VBProfiles highlights Ubl's role in the passing of landmark reforms related to FDA product review process and Medicare’s coverage and reimbursement of medical technologies.
Politico suggests that, if appointed to head PhRMA, Ubl would receive a "substantial raise from his $1.5 million in total compensation in 2013," pointing out that, in the same year, John Castellani "earned $3.6 million".
